ANNUAL REPORT

Improving lives through immunization

2016
Achieving Our Mission

to make vaccines more accessible, enable innovation and expand immunization across the globe.
# Table of Contents

2   Letter from the Chairman and the CEO  
3   Leadership  
4   Access & Uptake  
12  Knowledge & Innovation  
14  Research & Development  
16  Advocacy & Engagement  
19  Finances  
22  Awards & Recognition
2016: Refocusing on Immunization

Letter from the Chairman and the CEO

In 2016, the Sabin Vaccine Institute adopted a new mission, welcomed new leadership and set forth an ambitious strategic plan to advance our vision of a future free from vaccine-preventable diseases.

Following a comprehensive, six-month strategic planning process in partnership with Boston Consulting Group, Sabin’s Board of Trustees unanimously adopted a new strategic plan in December, which renews Sabin’s focus on vaccine-preventable diseases and aligns our activities with a new mission:

Our mission is to make vaccines more accessible, enable innovation and expand immunization across the globe.

Despite tremendous investments over the last decade, the benefits of immunization have not been fully realized. After examining the issues and assessing how Sabin can best contribute in the coming years, it became clear that we can have the greatest impact by focusing on immunization. Sabin’s new strategy builds on more than 20 years of experience working behind the scenes with countries to help them achieve their immunization goals through advocacy, education and as a trusted convener of the global health community.

Our work is guided by three strategic priorities: enabling vaccine access and uptake, advancing vaccine knowledge and innovation, and supporting research and development for immunization.

In order to focus fully on vaccine-preventable diseases, Sabin’s Board of Trustees made the decision in 2016 to conclude Sabin’s non-vaccine-based work in neglected tropical diseases. Over the last decade, Sabin helped put neglected tropical diseases onto the global agenda through the Global Network for Neglected Tropical Diseases, Sabin Foundation Europe and the END7 campaign, which mobilized political will and funding to end the most common neglected tropical diseases. This work is a proud chapter in Sabin’s legacy, and a strong network of global health organizations is well positioned to carry this progress forward. The policy and advocacy expertise we have built through these initiatives will be a valuable asset to Sabin as we continue, more focused than ever, to advance immunization at the global, regional and country levels.

In the spring of 2017, Dr. Peter J. Hotez resigned his role as President of Sabin Vaccine Institute to pursue his increasing responsibilities at Baylor College of Medicine and Texas Children’s Hospital. Peter has played a vital role in Sabin’s success in the last 17+ years, including a decade as Sabin’s President. The Sabin team, specifically the Board of Trustees, expresses its appreciation to Peter for his service and contributions to Sabin’s success.

For many years, Sabin partnered with The George Washington University, Baylor College of Medicine, Texas Children’s Hospital and other institutions to research and develop new vaccines for neglected and emerging diseases, led by Peter and Dr. Maria Elena Bottazzi. This spring, the Sabin Board of Trustees resolved to transfer these projects and all associated grants, contracts and intellectual property to Baylor College of Medicine, which continues this research at the Texas Children’s Hospital Center for Vaccine Development in Houston, Texas. Sabin’s leadership team and Board of Trustees remain committed to supporting research to identify innovative approaches to combat infectious and emerging threats. We are currently evaluating new research and development opportunities, seeking projects with transformative potential to improve lives through immunization.

As we began implementing our strategy in early 2017, Dr. Bruce Gellin joined our team in the newly created position of President of Global Immunization. Bruce served for 15 years as Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services. In his new role, Bruce is leading Sabin’s efforts to champion sustainable, evidence-based solutions to prevent disease through vaccination and drive partnerships in the global health community. Bruce’s breadth of vaccine experience and commitment to
improving global health through immunization bring great benefit to Sabin, to our stakeholders, and ultimately to the people and communities we serve around the world.

Sabin is a small organization with an outsized impact. By deliberately focusing on the areas in which we are uniquely positioned to make a difference, we will expand upon our past success to build sustainable, equitable access to immunization. Our 2016 Annual Report highlights our current activities to build sustainable immunization systems, support the development and introduction of new vaccines, gather evidence for policymaking, and shape the global conversation about vaccines.

Dr. Albert B. Sabin, developer of the oral live virus polio vaccine and namesake of the Sabin Vaccine Institute, dedicated himself to ensuring that research “not remain something beautiful on the shelves of libraries or like the works of art hanging in museums, but that it be used, as far as possible, to solve basic and human problems.”

This purpose still guides our work today. Energized by our clarity of purpose, in 2017 we have formed new partnerships, welcomed new leadership on our staff and board, and advanced our work to extend the benefits of immunization to all people, no matter who they are or where they live.

Axel Hoos, M.D., Ph.D.
Chairman,
Sabin Vaccine Institute;
Senior Vice President,
Oncology R&D,
GlaxoSmithKline Pharmaceuticals

Amy Finan
Chief Executive Officer

Bruce Gellin,
M.D., M.P.H.
President,
Global Immunization

Brian Davis,
C.P.A.
Chief Operating Officer
ACCESS & UPTAKE

Getting more vaccines to more people
Immunization is among the simplest, most cost-effective investments a nation can make for the health of its people. Sabin works with key decision makers and immunization experts at the country and global levels to build resilient, sustainable national immunization programs.

After a new vaccine is introduced in wealthy countries, it can take a decade or more for that vaccine to reach people in lower-income countries – often the people that need the vaccine most. Gavi, the Vaccine Alliance, and others have dramatically improved access to vaccines in the world’s poorest countries but much more can be done to expand immunization at the country level.

Sabin helps lay the groundwork for vaccine introduction by providing countries with the information they need to decide which vaccines to introduce and when. We help national leaders develop reliable, long-lasting financial solutions for immunization to protect the system against shocks and enable them to act quickly to protect the health of their people.

There is no “one size fits all” solution for immunization. Every country has unique experiences, perspectives and challenges. That’s why Sabin works alongside countries to generate and evaluate epidemiological and economic evidence to inform immunization decisions in response to countries’ needs and priorities.

Sabin brings together national government officials, policy makers, immunization specialists, researchers and advocates to provide decision makers with the data and expertise they need to make evidence-based decisions on vaccines. From establishing the burden of a disease to evaluating the impact and effectiveness of new vaccines, Sabin helps countries evaluate and streamline vaccine introduction and scale-up.

Collaboration across continents and sectors is critical to extend the benefits of immunization around the globe. Our international meetings, symposia and workshops offer a unique opportunity to bring everyone to the table to exchange ideas, identify shared priorities and form valuable connections. But our work is just beginning when the conference ends – Sabin works to accelerate vaccine research and introduction through collaboration, by mobilizing immunization champions at all levels and helping countries establish long-term policy solutions that will strengthen and protect immunization systems for generations to come.
Many lower-income countries rely on Gavi, the Vaccine Alliance, for significant immunization funding, but as their economies grow, countries are expected to scale up to full domestic financing. For nearly a decade, Sabin has helped countries establish the long-term, reliable funding necessary to maintain their immunization programs as donor funds dwindle.

In July 2016, Sabin held its third colloquium on sustainable immunization financing, convening more than 125 representatives from 17 countries in Kathmandu, Nepal, to discuss and develop innovative, long-term domestic financing solutions for immunization. Participants celebrated the 2016 passage of Nepal’s immunization law, which introduces a national fund for immunization. Following five years of workshops, briefings and peer exchanges by Sabin to build political will through evidence on the value of vaccination, its passage makes Nepal the third of Sabin’s partner countries in as many years to pass a law establishing and protecting financing for immunization. In 2017, Madagascar became the fourth, passing its National Immunization Fund Law after six years of focused, dedicated work.

4 of Sabin’s partner countries have passed legislation establishing and safeguarding funding for immunization

“Sabin has accompanied us from the beginning of the sustainable immunization financing process,” – Health ministry official Dr. Aro Tafosahasina Rajioelina of Madagascar
Sabin invited and convened lawmakers from eight countries at the 2016 Ministerial Conference on Immunization in Africa where they drafted and signed a parliamentary statement committing to strengthen immunization programs through advocacy, legislation and continent-wide collaboration; Madagascar’s parliamentarians were able to leverage this commitment to accelerate approval of their immunization bill.

Sabin expanded on nearly a decade of progress in sustainable immunization financing in 2016, launching an initiative in partnership with the U.S. Centers for Disease Control and Prevention in the Democratic Republic of Congo, Kenya and Senegal.

Sabin’s mobilization of immunization champions paid dividends in 2016, when the Democratic Republic of Congo's parliamentary network, founded in 2012 with the help of Sabin, protected the national immunization budget against a proposed cut of 21%.

“We can no longer have a Democratic Republic of the Congo where children die because of vaccine-preventable diseases when the vaccines are there.”

– Hon. Grégoire Lusenge, President of the DRC Parliamentary Support Network for Immunization
A third of the world’s population is at risk of contracting typhoid, a deadly bacterial infection spread through contaminated food and water. Typhoid poses the greatest risk to children in low- and middle-income countries – a risk made more urgent by the rising threat of drug resistance. Long-awaited conjugate vaccines could dramatically reduce the global burden of typhoid, improving the lives of tens of millions.

For 10 years, Sabin’s Coalition against Typhoid has provided a platform to guide typhoid vaccine policy and prepare for the introduction of new vaccines. Most recently, Sabin brought together more than 250 researchers and advocates in Uganda at the Coalition’s 10th conference, with attendees representing a record 39 countries. Data presented at the conference have informed discussions at the World Health Organization, where experts are reviewing recommendations on the use of typhoid vaccines. Changes to these recommendations could reshape global strategy on typhoid fever and come as early as 2018. Sabin will hold its next typhoid conference in 2019 at a critical time, as countries prepare to introduce new vaccines that will profoundly impact prevention and control efforts.
Sabin is leading a large, landmark surveillance study to establish the burden of typhoid and paratyphoid in Asia, generating evidence that will help countries evaluate the impact of typhoid conjugate vaccine introduction. The team presented Phase I findings at the American Society of Tropical Medicine and Hygiene Annual Meeting in 2016 and initial Phase II data at the conference in Uganda.

Sabin is now joining forces with the Typhoid Vaccine Acceleration Consortium (TyVAC) to accelerate the introduction of the new typhoid conjugate vaccines and advance integrated solutions to take on typhoid in low- and middle-income countries.

Read personal stories collected by Sabin and Coalition members of people whose lives have been affected by typhoid, from five-year-old Rasmina Tamang in Nepal to nurse Sarah Mwanamanga in Malawi.
Introduction & Expansion of Vaccines

Fostering dialogue among national and global health leaders to drive equitable, measurable and sustainable results

In order to make informed decisions about vaccine introduction and implementation, countries need high-quality information about the health and economic burden of disease and the range and anticipated impact of available interventions, including vaccines. By establishing and sharing best practices and evidence through our international scientific meetings, Sabin helps countries prepare for, evaluate and streamline vaccine introduction and scale-up. For example, Sabin has convened the International Rotavirus Symposium every two years since 2004 to support future policymaking decisions on rotavirus prevention.

Diarrheal diseases remain the second-leading cause of death from infections among children. Rotavirus diarrhea kills more than 200,000 children each year and hospitalizes millions more. In the decade since the introduction of the current generation of rotavirus vaccines, 81 countries have introduced vaccines against rotavirus, and current estimates predict immunization will avert 2.4 million deaths between 2007 and 2025. But the full potential of these vaccines has yet to be realized. In September 2016, at the 12th International Rotavirus Symposium in Melbourne, Australia, 350 experts from 50 countries examined new surveillance data.
and studies demonstrating the impact of rotavirus vaccination, which will inform public health agendas related to prevention of rotavirus. The next conference will be held in Budapest, Hungary, in 2018.

In May 2016, Sabin gathered nearly 50 immunization experts and civil society leaders from 23 countries in Siena, Italy, to chart the path to elimination of measles and rubella. Since 2012, Sabin has been part of the Measles and Rubella Initiative, a global partnership to stop measles and rubella. Measles vaccination prevented an estimated 20.3 million deaths from 2000-2015, yet measles remains one of the leading causes of death of young children, causing 134,000 child deaths in 2015. Due to its wide geographic spread and high level of contagiousness, measles elimination efforts face many hurdles, from health system challenges and vaccine availability issues to recent outbreaks spurred by vaccine hesitancy.

While rubella is generally a mild disease, it can be devastating to a developing baby when a pregnant woman is infected. Known as congenital rubella syndrome, the baby can be born with a number of serious and life-threatening physical and mental birth defects including deafness and developmental delays. Rubella causes an estimated 100,000 cases of Congenital Rubella Syndrome each year. Although vaccines have been available since the 1960s, less than half of the world’s children are vaccinated against rubella. At the meeting in Siena, representatives met to identify challenges and best practices for achieving high immunization coverage among older children and adults to reduce the burden of measles and rubella worldwide.

Sabin supports surveillance programs and conducts research to generate essential evidence for well-designed, efficiently implemented immunization programs, supplying decision makers with the data and expertise they need to make evidence-based decisions on vaccines. Since 2009, Sabin, in partnership with the Pan American Health Organization and the U.S. Centers for Disease Control and Prevention, has worked with six countries in Latin America to strengthen surveillance for pertussis (also known as whooping cough). The project included training more than 600 physicians in Panama to detect and report pertussis cases, and resulted in more frequent, more accurate reporting in Argentina, where data from the study led the Ministry of Health to introduce a maternal dose of pertussis vaccine to protect the youngest and most vulnerable from pertussis.
Preparing for what's next
Sabin is building a healthier future by amplifying reliable information on vaccines and arming immunization professionals with the latest information in vaccine science and policy.

Most immunization managers are trained as doctors or nurses but have never received management training – and their management skills are critical to the effectiveness, efficiency and impact of the immunization programs they oversee. To address this need, Sabin established the International Association of Immunization Managers (IAIM) in 2013 – now the world’s largest professional network of immunization managers. IAIM held its first regional meeting in Asia in 2016, bringing together more than 175 participants from 21 countries across Asia and the Pacific in Beijing, China, to discuss how to overcome common management challenges in immunization systems, with a special focus on the elimination of measles.

In early 2017, Sabin convened 70 immunization managers from 30 countries in Madrid, Spain, to discuss an issue of increasing concern to public health experts around the world: vaccine acceptance and demand. At the meeting, immunization managers compared experiences and experts shared tools to help immunization professionals understand the values guiding the vaccination decisions of the populations they serve and communication strategies to build immunization program resilience. Two months later, more than 60 percent of surveyed attendees said they have already applied something they learned at the meeting to monitor and promote vaccine confidence, and a third of respondents intend to do so.

To expand upon this work, Sabin relaunched IAIM in 2017 as the IAIM Network. The new IAIM Network will serve health professionals involved in immunization at all levels and across all sectors, focusing on management and leadership skills. The Network is designed to reach more immunization professionals and foster the exchange of ideas and best management practices to further the goal of strengthening immunization systems around the world.

As more vaccines become available, it becomes more and more crucial that officials in charge of immunization services understand the current guidelines, recommendations and policies regarding vaccinations in the context of the needs and priorities of their countries. In December 2016, 30 delegates from 12 countries gathered at the VI Ciro de Quadros Vaccinology Course for Latin America to hear from more than 20 expert speakers in vaccinology and discuss the fundamentals of epidemiology and immunology, current vaccine and immunization recommendations, issues surrounding vaccination and immunization campaigns, funding mechanisms and effective use of communications.

"19.4 million infants worldwide are still missing out on basic vaccines. By delivering evidence-based resources to health professionals, we are working to close that gap and ensure every child receives the benefits of immunization."

– Dr. Bruce Gellin, President, Global Immunization, Sabin Vaccine Institute
RESEARCH & DEVELOPMENT

Advancing immunization through science
Focusing on infectious and emerging diseases that have high human impact but may lack traditional market incentives, Sabin is committed to supporting research to identify innovative solutions to improve more lives more quickly through immunization.

Sabin supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health.

For more than 15 years, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) – a joint initiative of the Sabin Vaccine Institute, the Baylor College of Medicine, Texas Children’s Hospital and other partners – conducted research to develop new, low-cost vaccines for diseases impacting the world’s most neglected and vulnerable populations. The Sabin PDP focused on vaccine candidates for human hookworm, schistosomiasis, onchocerciasis, SARS and Chagas disease, among others.

In March 2017, the Sabin Board of Trustees voted to transfer these projects and all associated grants, contracts and intellectual property to Baylor College of Medicine, where former Sabin President Dr. Peter J. Hotez plans to continue this research at the Texas Children’s Hospital Center for Vaccine Development in Houston, Texas.

Sabin remains committed to supporting research to identify innovative solutions to improve human life through immunization. With new management and a renewed dedication to improving human health through immunization, Sabin is evaluating opportunities to engage in innovative research and form new partnerships.

“The most powerful health intervention may not have been invented yet, and the most pressing threat may be one we’ve never heard of. Through immunization research and development, Sabin will shape the future of health from the front lines.”

– Amy Finan, CEO, Sabin Vaccine Institute
ADVOCACY & ENGAGEMENT

Sabin's Legacy in NTDs
Ten years ago, Sabin launched the Global Network for Neglected Tropical Diseases to accelerate the global effort to control and eliminate neglected tropical diseases (NTDs), parasitic and infectious diseases afflicting more than 1 billion people.

After a decade of progress, the Global Network for Neglected Tropical Diseases concluded its activities in 2016. Through the Global Network, Sabin shaped the international dialogue about NTDs, culminating at an international conference in November 2016 hosted by the Pontifical Council for Health Care Workers and planned in partnership with Sabin. 500 leading scientific researchers, Catholic officials and policy makers from around the globe gathered at the Vatican to address NTDs and rare diseases. At the conclusion of the conference, remarks from Pope Francis were shared with conference participants, calling for international commitment to treating and preventing NTDs and rare diseases.

Since 2006, the Global Network has brought NTDs onto the global agenda, generating political will among endemic and donor countries and working to obtain a place for NTDs in the Sustainable Development Goals. The Global Network expanded treatment for NTDs across more than 80 countries by helping countries draft national plans to implement and expand treatment programs, secured more than $165 million in funding to support NTD treatment, and galvanized advocates for political and financial commitments to fight NTDs, from heads of state to the general public.

The award-winning END7 campaign built a grassroots movement to garner public support for the effort to end the seven most common NTDs through advocacy, fundraising and creative digital and social media promotion. The campaign helped provide treatment for more than 50 million people in over a dozen countries by raising $1.2 million from the public to support NTD treatment programs.

END7 facilitated more than 20,000 grassroots advocacy actions, introduced more than 7 million people to NTDs through the cutting-edge PSA “How to Shock a Celebrity” and recruited the next generation of global health leaders. The campaign mobilized more than 1,500 students from 345 universities in 29 countries to plan advocacy, awareness and fundraising events and lead dedicated campus chapters to expand the reach of the campaign. As we shift our resources to fully focus on immunization, we have concluded the END7 campaign and taken steps to connect supporters with organizations continuing the fight against NTDs. We are grateful to everyone who joined this historic effort and are proud of everything we achieved together.

Since its founding in 2011, Sabin Foundation Europe, Sabin’s sister organization, has mobilized political will and funding in the United Kingdom and across Europe to combat diseases of poverty. The Foundation has played a leading role in securing new funding commitments for NTDs and engaged and cultivated parliamentary champions, who have become vocal advocates for continued UK leadership across NTD treatment and research for new tools. The Foundation and Sabin have worked together to influence parliamentary and government-level discussions on global health research and development in the United Kingdom, Germany, the Netherlands and with the European Commission. These have stimulated national, regional and global decisions on financing for research and development of new tools. Considering strategic shifts, Sabin Foundation Europe’s Board of Trustees has decided to conclude operations in 2017.

Over the last 10 years, Sabin helped build a movement that has succeeded at bringing several NTDs to the brink of elimination. Increased treatment has improved countless lives, but for some diseases, new tools and strategies are required. We are proud of our legacy in NTDs, and a strong network of global health organizations is well positioned to carry this work forward.
Student Leadership

At the 2016 Student Advocacy Day on Capitol Hill, 40 students from 15 universities participated in some 40 meetings with key congressional offices to protect U.S. funding commitments for NTDs, concluding with a keynote address from Barbara Bush. In 2017, 25 students converged on the Hill for the third annual Student Advocacy Day, with support from Uniting to Combat NTDs and other NTD Roundtable partners.
10 years of four-star accountability & transparency
Sabin’s total operating revenue for 2016 exceeded $15.2 million, with net assets greater than $15.4 million. Sabin invested in its future in 2016, undertaking an in-depth strategic planning process in partnership with Boston Consulting Group. In December 2016, Sabin’s Board of Trustees unanimously adopted a new strategic plan, renewing our focus on vaccine-preventable diseases.

We are proud to have received Charity Navigator’s highest rating for accountability and transparency for 10 consecutive years. We will continue to hold ourselves to the highest standards as we strive to achieve our vision of a world free from vaccine-preventable diseases. See a snapshot of our 2016 finances below or read the full audit report.

How we used our funds in 2016

- **11%**
  - $2,120,667 on organizational management and administration

- **4%**
  - $696,389 on strategic planning

- **2%**
  - $419,235 on resource development & fundraising to support future growth

- **83%**
  - $15,940,607 on programs
Sabin’s Board of Trustees and executive leadership are fully committed to responsible and effective stewardship of donor funding. For the 10th consecutive year, Sabin received Charity Navigator’s highest rating possible for consistently executing our mission in a fiscally responsible way.

This information has been summarized from Sabin’s audited financial statements. Sabin’s full audit report, completed by Rogers & Co, LLP, is available at www.sabin.org.
Recognition

Peter J. Hotez M.D., Ph.D.

For more than two-thirds of our history, Dr. Peter Hotez has been affiliated with Sabin as a leading figure and contributed to Sabin’s many accomplishments in global health. After 17 years Peter left the Sabin leadership team to concentrate on new efforts at the Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas.

Peter joined Sabin in 2000 as the Chair of the Scientific Advisory Committee to lead vaccine research and development efforts, becoming President in 2007. As President, Peter and his fellow Board Trustees led Sabin to embody Dr. and Mrs. Sabin’s vision of alleviating the burden of disease for the world’s poorest people.

Sabin and Peter have worked tirelessly with international organizations to bring global attention to these forgotten people and the NTDs that afflict them. Recognizing that there are few, if any, incentives to develop vaccines for the very poor, in 2000 - led by Peter - Sabin launched the first non-profit product development partnership (PDP) focused on safe, effective and low-cost vaccines for NTDs. Moving the Sabin PDP labs to Houston in 2011 to the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, Peter has continued to lead the organization’s research efforts on “antipoverty vaccines” for eight different neglected and infectious diseases.

In addition to his role with Sabin and his research, in August 2011, Peter became the founding dean of Baylor College of Medicine’s National School of Tropical Medicine where he is training, but also inspiring, the next generation of scientists and global health leaders. As a Science Envoy with the Obama Administration from 2015-2016, Peter used vaccines as a diplomatic tool, recalling how Albert Sabin reached out to the former Soviet Union to make the oral polio vaccine available to its people during the Cold War.

With his increasing responsibilities in Texas, Peter resigned as President of the Sabin Vaccine Institute in 2017. Sabin’s Board of Trustees and staff are enormously appreciative of Peter’s contributions over the years. We wish Peter continued success with his new endeavors and look forward to his continued contributions to global health.

Sabin Foundation Europe Board of Trustees

Since 2011, Sabin Foundation Europe has worked to raise awareness and funding in the United Kingdom and across Europe to combat diseases of poverty, through the valuable leadership and counsel of the Foundation’s Board of Trustees. Thanks to the Board’s leadership in establishing the Sabin City Group, the Foundation was able to cultivate new global corporate citizens in the fight against NTDs, raising more than £50,000 over the last four years for treatment programs in India and Guyana.

Awards

Sabin Gold Medal Award
Every year, Sabin recognizes a distinguished member of the public health community who has made extraordinary contributions in the field of vaccinology or a complementary field. The Sabin Gold Medal Award commemorates the legacy of Dr. Albert B. Sabin, the developer of the oral polio vaccine that has helped bring poliovirus to the brink of eradication.

Sabin awarded its 2016 Albert B. Sabin Gold Medal Award to George R. Siber, M.D., for his outstanding contributions to immunology and infectious disease research through the development of life-saving vaccines for childhood diseases, including pneumococcus, Hib and meningococcus. Gavi, the Vaccine Alliance, estimates that, between 2011 and 2020, Dr. Siber’s pneumococcal conjugate vaccine will have prevented 1.5 million deaths in Gavi-supported countries. Dr. Mathuram Santosham, recipient of the 2014 Sabin Gold Medal Award, presented the award to Dr. Siber in Baltimore, MD, in front of an audience of nearly 100 friends and colleagues.

2016 marked the 23rd year that Sabin has bestowed this award. Past recipients of the Sabin Gold Medal Award include Roger I. Glass, M.D., Ph.D.; Anne A. Gershon, M.D.; Rino Rappuoli, Ph.D.; Stanley A. Plotkin, M.D.; and Maurice R. Hilleman, Ph.D.

In Memory

D.A. Henderson, M.D.
Dr. Donald “D.A.” Henderson, who led the international effort to eradicate smallpox, died in August 2016 at age 87. The success of the campaign against smallpox inspired the WHO and others to expand immunization programs to children all over the world. One of the most influential global public health figures of the century, among his honors and awards are the first Albert B. Sabin Gold Medal Award in 1994 and the Presidential Medal of Freedom in 2002.

Heloisa Sabin
In October 2016, the Sabin Vaccine Institute joined a global community of friends, partners and global health advocates in celebrating the life of Heloisa Sabin (née Dunshee de Abranches), who passed away at the age of 98. Wife of the late Dr. Albert B. Sabin, who developed the oral polio vaccine, Heloisa shared her late husband’s dedication to the elimination of needless human suffering and poverty. Heloisa Sabin was an outspoken advocate in the effort to end vaccine preventable diseases. Following Albert’s death, Heloisa dedicated her life to continuing the work and legacy of her husband. Highlighting this commitment, she founded the Sabin Vaccine Institute in 1993 with Dr. H.R. Shepherd, Dr. Robert Chanock and Dr. Philip Russell. She served as a trustee or honorary trustee of the Institute until the time of her death. She was laid to rest next to Albert at the Arlington National Cemetery. Heloisa’s legacy and commitment will continue to inspire us all for many years to come.
Thank you to all of our partners and donors. We are grateful for your support, which makes Sabin’s important work possible.

Learn more or become a supporter at sabin.org